Kazia Therapeutics Limited (KZIA)
USD 3.82
(-2.8%)
USD 3.82
(-2.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 28.08 Million AUD | -19.66% |
| 2022 | 34.95 Million AUD | -39.82% |
| 2021 | 58.08 Million AUD | 151.86% |
| 2020 | 23.06 Million AUD | 8.91% |
| 2019 | 21.17 Million AUD | -24.84% |
| 2018 | 28.17 Million AUD | -21.54% |
| 2017 | 35.91 Million AUD | 1.11% |
| 2016 | 35.51 Million AUD | -23.02% |
| 2015 | 46.13 Million AUD | 890.31% |
| 2014 | 4.65 Million AUD | -18.95% |
| 2013 | 5.74 Million AUD | -36.02% |
| 2012 | 8.98 Million AUD | -29.4% |
| 2011 | 12.72 Million AUD | -34.02% |
| 2010 | 19.29 Million AUD | -49.02% |
| 2009 | 37.84 Million AUD | -12.76% |
| 2008 | 43.37 Million AUD | -15.64% |
| 2007 | 51.41 Million AUD | 0.59% |
| 2006 | 51.11 Million AUD | -23.95% |
| 2005 | 67.21 Million AUD | -12.65% |
| 2004 | 76.94 Million AUD | 51.99% |
| 2003 | 50.62 Million AUD | -18.26% |
| 2002 | 61.93 Million AUD | -48.36% |
| 2001 | 119.94 Million AUD | 84.46% |
| 2000 | 65.02 Million AUD | 16.37% |
| 1999 | 55.87 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 24.38 Million AUD | 0.0% |
| 2023 FY | 28.08 Million AUD | -19.66% |
| 2023 Q4 | 28.08 Million AUD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 27.83 Million AUD | 0.0% |
| 2022 Q3 | 35.88 Million AUD | -19.66% |
| 2022 Q2 | 44.66 Million AUD | 0.0% |
| 2022 Q4 | 35.88 Million AUD | 0.0% |
| 2022 FY | 34.95 Million AUD | -39.82% |
| 2022 Q1 | 44.66 Million AUD | -23.1% |
| 2021 FY | 58.08 Million AUD | 151.86% |
| 2021 Q2 | 39.61 Million AUD | 0.0% |
| 2021 Q4 | 58.08 Million USD | 0.0% |
| 2020 FY | 23.06 Million AUD | 8.91% |
| 2020 Q1 | 20.49 Million AUD | -3.2% |
| 2020 Q2 | 20.49 Million AUD | 0.0% |
| 2020 Q3 | 23.06 Million AUD | 12.51% |
| 2020 Q4 | 23.06 Million AUD | -0.0% |
| 2019 Q2 | 25.59 Million AUD | 0.0% |
| 2019 FY | 21.17 Million AUD | -24.84% |
| 2019 Q1 | 25.59 Million AUD | -9.15% |
| 2019 Q3 | 21.17 Million AUD | -17.26% |
| 2019 Q4 | 21.17 Million AUD | 0.0% |
| 2018 Q1 | 37.81 Million AUD | 5.31% |
| 2018 Q2 | 37.81 Million AUD | 0.0% |
| 2018 Q3 | 28.17 Million AUD | -25.5% |
| 2018 Q4 | 28.17 Million AUD | -0.0% |
| 2018 FY | 28.17 Million AUD | -21.54% |
| 2017 FY | 35.91 Million AUD | 1.11% |
| 2017 Q4 | 35.91 Million AUD | 0.0% |
| 2017 Q2 | 45.25 Million AUD | 0.0% |
| 2016 Q2 | 42.85 Million AUD | 0.0% |
| 2016 Q1 | 42.85 Million AUD | -7.11% |
| 2016 FY | 35.51 Million AUD | -23.02% |
| 2016 Q3 | 35.51 Million AUD | -17.13% |
| 2016 Q4 | 35.51 Million AUD | 0.0% |
| 2015 Q1 | 9.93 Million AUD | 113.1% |
| 2015 FY | 46.13 Million AUD | 890.31% |
| 2015 Q3 | 46.13 Million AUD | 364.62% |
| 2015 Q2 | 9.93 Million AUD | 0.0% |
| 2015 Q4 | 46.14 Million AUD | 0.0% |
| 2014 Q2 | 8.84 Million AUD | 0.0% |
| 2014 FY | 4.65 Million AUD | -18.95% |
| 2014 Q4 | 4.66 Million AUD | 0.02% |
| 2014 Q3 | 4.65 Million AUD | -47.31% |
| 2014 Q1 | 8.84 Million AUD | 53.8% |
| 2013 FY | 5.74 Million AUD | -36.02% |
| 2013 Q4 | 5.74 Million AUD | 0.01% |
| 2013 Q2 | 4.23 Million AUD | 0.0% |
| 2013 Q1 | 4.23 Million AUD | -52.84% |
| 2013 Q3 | 5.74 Million AUD | 35.64% |
| 2012 Q2 | 13.57 Million AUD | 0.0% |
| 2012 Q4 | 8.98 Million AUD | 0.0% |
| 2012 FY | 8.98 Million AUD | -29.4% |
| 2011 FY | 12.72 Million AUD | -34.02% |
| 2011 Q2 | 12.8 Million AUD | 0.0% |
| 2011 Q4 | 12.72 Million AUD | 0.0% |
| 2010 Q4 | 19.29 Million AUD | 0.0% |
| 2010 Q2 | 25.26 Million AUD | 0.0% |
| 2010 FY | 19.29 Million AUD | -49.02% |
| 2009 FY | 37.84 Million AUD | -12.76% |
| 2009 Q4 | 37.84 Million AUD | 0.0% |
| 2009 Q2 | 52.85 Million AUD | 0.0% |
| 2008 Q2 | 57.28 Million AUD | 0.0% |
| 2008 Q4 | 43.37 Million AUD | 0.0% |
| 2008 FY | 43.37 Million AUD | -15.64% |
| 2007 Q1 | 20.95 Million USD | -59.0% |
| 2007 FY | 51.41 Million AUD | 0.59% |
| 2007 Q2 | 62.07 Million AUD | 196.17% |
| 2007 Q4 | 51.41 Million AUD | 0.0% |
| 2006 Q4 | 51.11 Million AUD | 0.0% |
| 2006 FY | 51.11 Million AUD | -23.95% |
| 2006 Q2 | 61.95 Million AUD | 0.0% |
| 2005 FY | 67.21 Million AUD | -12.65% |
| 2005 Q4 | 67.21 Million AUD | 0.0% |
| 2005 Q2 | 67.78 Million AUD | 0.0% |
| 2004 FY | 76.94 Million AUD | 51.99% |
| 2004 Q4 | 76.94 Million AUD | 0.0% |
| 2003 Q4 | 50.62 Million AUD | 0.0% |
| 2003 FY | 50.62 Million AUD | -18.26% |
| 2002 FY | 61.93 Million AUD | -48.36% |
| 2002 Q4 | 61.93 Million AUD | 0.0% |
| 2001 FY | 119.94 Million AUD | 84.46% |
| 2001 Q4 | 119.94 Million AUD | 0.0% |
| 2000 Q4 | 65.02 Million AUD | 0.0% |
| 2000 FY | 65.02 Million AUD | 16.37% |
| 1999 FY | 55.87 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -784.294% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -2380.674% |
| XOMA Corporation | 234.3 Million USD | 88.013% |
| Mesoblast Limited | 669.15 Million USD | 95.803% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 91.759% |
| Aptorum Group Limited | 20.64 Million USD | -36.071% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -1281.296% |
| HilleVax, Inc. | 344.43 Million USD | 91.846% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 95.041% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 0.662% |
| Precision BioSciences, Inc. | 159.78 Million USD | 82.423% |
| Dyadic International, Inc. | 8.21 Million USD | -241.701% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -62.389% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 95.675% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 11.515% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 71.249% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 92.093% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 95.752% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 83.529% |
| IGM Biosciences, Inc. | 423.41 Million USD | 93.367% |
| Opthea Limited | 188.79 Million USD | 85.124% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 62.666% |
| Abeona Therapeutics Inc. | 64 Million USD | 56.118% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 81.817% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 96.629% |
| NextCure, Inc. | 129.41 Million USD | 78.299% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -93.602% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 80.5% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 62.686% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 93.459% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 83.3% |
| Senti Biosciences, Inc. | 119.48 Million USD | 76.495% |
| Apollomics, Inc. | 55.38 Million USD | 49.293% |
| PureTech Health plc | 693.97 Million USD | 95.953% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 23.534% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 86.907% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 95.122% |
| ChromaDex Corporation | 54.96 Million USD | 48.903% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -282.363% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 88.38% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 83.012% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -252.005% |
| Gritstone bio, Inc. | 177.76 Million USD | 84.201% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -191.693% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 94.452% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 61.894% |
| Fortress Biotech, Inc. | 167.52 Million USD | 83.235% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -422.223% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 70.821% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 96.255% |
| Celcuity Inc. | 191.21 Million USD | 85.313% |
| ContextLogic Inc. | 423 Million USD | 93.36% |
| GH Research PLC | 226.3 Million USD | 87.589% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 82.592% |
| Cassava Sciences, Inc. | 151.66 Million USD | 81.482% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -218.969% |
| ImmuCell Corporation | 43.8 Million USD | 35.89% |
| Amarin Corporation plc | 831.68 Million USD | 96.623% |
| TG Therapeutics, Inc. | 329.58 Million USD | 91.479% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 80.928% |
| Acelyrin, Inc. | 742.69 Million USD | 96.218% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -378.269% |
| Seer, Inc. | 436.26 Million USD | 93.562% |
| Novavax, Inc. | 1.85 Billion USD | 98.486% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 93.214% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.753% |
| AnaptysBio, Inc. | 452.38 Million USD | 93.792% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -13.055% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 88.862% |
| AbCellera Biologics Inc. | 1.48 Billion USD | 98.113% |
| CorMedix Inc. | 82.05 Million USD | 65.775% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 90.793% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -63.978% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.915% |
| Aptose Biosciences Inc. | 12.92 Million USD | -117.335% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -27.0% |
| Soligenix, Inc. | 9.79 Million USD | -186.662% |
| Century Therapeutics, Inc. | 360.69 Million USD | 92.214% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 96.331% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -443.265% |
| Kura Oncology, Inc. | 448.93 Million USD | 93.744% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 83.797% |
| Ardelyx, Inc. | 297.57 Million USD | 90.562% |
| Ainos, Inc. | 31.84 Million USD | 11.798% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 89.68% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 74.678% |
| Prothena Corporation plc | 696.38 Million USD | 95.967% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 86.31% |
| Autolus Therapeutics plc | 375.38 Million USD | 92.518% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 88.839% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 90.062% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 42.837% |
| Celularity Inc. | 143.88 Million USD | 80.481% |
| Rallybio Corporation | 115.62 Million USD | 75.709% |
| GRI Bio, Inc. | 2.95 Million USD | -850.107% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -164.824% |
| Omeros Corporation | 378.26 Million USD | 92.575% |
| INmune Bio, Inc. | 57 Million USD | 50.729% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 87.378% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 66.542% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -7.537% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -308.025% |
| Humacyte, Inc. | 128.22 Million USD | 78.097% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 83.031% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 95.539% |
| Immunocore Holdings plc | 597 Million USD | 95.296% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 10.153% |
| Verastem, Inc. | 149.71 Million USD | 81.241% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 94.516% |
| Histogen Inc. | 19.07 Million USD | -47.251% |
| Surrozen, Inc. | 46.08 Million USD | 39.051% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 97.323% |
| Organovo Holdings, Inc. | 6.34 Million USD | -342.356% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -551.837% |
| IO Biotech, Inc. | 150.71 Million USD | 81.366% |
| MEI Pharma, Inc. | 41.37 Million USD | 32.12% |
| GT Biopharma, Inc. | 14.1 Million USD | -99.059% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 92.262% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -55.215% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 88.928% |
| Summit Therapeutics Inc. | 202.94 Million USD | 86.161% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -239.891% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 83.567% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -122.691% |
| Turnstone Biologics Corp. | 112.81 Million USD | 75.105% |
| Pulmatrix, Inc. | 33.95 Million USD | 17.294% |
| Synaptogenix, Inc. | 31.11 Million USD | 9.734% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -130.509% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 94.876% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 80.061% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 97.841% |
| Cytokinetics, Incorporated | 824.31 Million USD | 96.593% |
| Exelixis, Inc. | 2.94 Billion USD | 99.045% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 92.296% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 96.439% |
| Evogene Ltd. | 51.1 Million USD | 45.04% |
| Replimune Group, Inc. | 487.72 Million USD | 94.242% |
| PDS Biotechnology Corporation | 59.39 Million USD | 52.711% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -195.004% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 70.554% |
| ESSA Pharma Inc. | 149.12 Million USD | 81.166% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -57.232% |
| BioLineRx Ltd. | 63.92 Million USD | 56.065% |
| Avid Bioservices, Inc. | 336.55 Million USD | 91.655% |
| Insmed Incorporated | 1.32 Billion USD | 97.888% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 77.287% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 95.003% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 70.962% |
| MediWound Ltd. | 66.45 Million USD | 57.741% |
| MiMedx Group, Inc. | 239.04 Million USD | 88.251% |
| OmniAb, Inc. | 401.98 Million USD | 93.013% |
| Alector, Inc. | 621.82 Million USD | 95.483% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 92.168% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 98.524% |
| Mereo BioPharma Group plc | 66.49 Million USD | 57.766% |
| Zai Lab Limited | 1.03 Billion USD | 97.29% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 94.13% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 95.418% |
| Aura Biosciences, Inc. | 255.07 Million USD | 88.989% |
| Immunic, Inc. | 54.29 Million USD | 48.277% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 82.987% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 89.451% |
| Veracyte, Inc. | 1.13 Billion USD | 97.532% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -137.551% |
| FibroGen, Inc. | 423.52 Million USD | 93.369% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -699.464% |
| Allakos Inc. | 243.61 Million USD | 88.471% |
| scPharmaceuticals Inc. | 94.47 Million USD | 70.274% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 89.101% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 95.481% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -492.939% |
| NLS Pharmaceutics AG | 1.84 Million USD | -1420.879% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -417.272% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 94.572% |
| Precigen, Inc. | 151.04 Million USD | 81.406% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.355% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 88.069% |
| Incyte Corporation | 6.78 Billion USD | 99.586% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -4346.756% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 77.683% |
| XBiotech Inc. | 227.24 Million USD | 87.641% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 81.751% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 70.554% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -48.413% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 98.74% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 95.16% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 74.576% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 80.305% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 90.177% |
| Agenus Inc. | 313.91 Million USD | 91.053% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -104.824% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 78.036% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 92.648% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 98.116% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 92.302% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -810.678% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 94.567% |
| UroGen Pharma Ltd. | 178.31 Million USD | 84.249% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -50.92% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 94.034% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -162.106% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 48.65% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -26.789% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 87.7% |
| Chimerix, Inc. | 212.77 Million USD | 86.8% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 73.859% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 13.052% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -260.817% |
| Pluri Inc. | 39.52 Million USD | 28.947% |
| Cue Biopharma, Inc. | 61.53 Million USD | 54.355% |
| MeiraGTx Holdings plc | 458.16 Million USD | 93.87% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -23.995% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -229.667% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 59.018% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -55.64% |
| CalciMedica, Inc. | 12.18 Million USD | -130.49% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 90.97% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 95.032% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -3.46% |
| NLS Pharmaceutics AG | 1.84 Million USD | -1420.879% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 78.427% |
| Nutriband Inc. | 7.51 Million USD | -273.614% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 64.428% |
| Vor Biopharma Inc. | 209.82 Million USD | 86.615% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.611% |
| ProKidney Corp. | 420.55 Million USD | 93.322% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 48.781% |
| Daré Bioscience, Inc. | 21.28 Million USD | -31.965% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 94.86% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -247.331% |
| Bicycle Therapeutics plc | 595.34 Million USD | 95.283% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 93.023% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 0.407% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 98.655% |
| Atai Life Sciences N.V. | 293.47 Million USD | 90.43% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 82.784% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 77.958% |
| MediciNova, Inc. | 66.26 Million USD | 57.62% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 68.066% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -529.379% |
| GeoVax Labs, Inc. | 9.28 Million USD | -202.537% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 92.154% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 95.226% |
| Biomea Fusion, Inc. | 199.92 Million USD | 85.952% |
| RenovoRx, Inc. | 1.46 Million USD | -1815.769% |
| Erasca, Inc. | 395.29 Million USD | 92.895% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 94.21% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -283.94% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 91.737% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 94.664% |
| bluebird bio, Inc. | 619.16 Million USD | 95.464% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 89.886% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 27.391% |
| Imunon, Inc. | 21.91 Million USD | -28.137% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.589% |
| BioAtla, Inc. | 119.65 Million USD | 76.529% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 95.631% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 70.725% |
| DBV Technologies S.A. | 182.98 Million USD | 84.652% |
| Fortress Biotech, Inc. | 167.52 Million USD | 83.235% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 95.532% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 87.305% |
| aTyr Pharma, Inc. | 122.06 Million USD | 76.992% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 94.273% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -85.288% |
| Galecto, Inc. | 38.22 Million USD | 26.531% |
| Akari Therapeutics, Plc | 4.35 Million USD | -544.895% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -64.845% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 98.38% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 87.759% |
| Entera Bio Ltd. | 11.76 Million USD | -138.718% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 96.44% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 62.238% |
| Xencor, Inc. | 952.69 Million USD | 97.052% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 70.502% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 72.981% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -247.973% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 95.669% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -810.678% |
| Portage Biotech Inc. | 7.77 Million USD | -261.038% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -529.379% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 89.859% |
| OncoCyte Corporation | 74.89 Million USD | 62.499% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -385.345% |
| Purple Biotech Ltd. | 44.3 Million USD | 36.605% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 17.702% |
| Onconetix, Inc. | 88.82 Million USD | 68.38% |
| MacroGenics, Inc. | 306.82 Million USD | 90.846% |
| Tharimmune, Inc. | 10.94 Million USD | -156.57% |
| Genprex, Inc. | 10.67 Million USD | -163.202% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 93.003% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 94.34% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 47.94% |
| Prime Medicine, Inc. | 193.85 Million USD | 85.512% |
| Aditxt, Inc. | 44.57 Million USD | 36.998% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -1057.674% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -574.243% |
| OKYO Pharma Limited | 1.54 Million USD | -1722.217% |
| Savara Inc. | 177.56 Million USD | 84.183% |
| Curis, Inc. | 77.28 Million USD | 63.659% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 56.082% |
| Adagene Inc. | 115.72 Million USD | 75.732% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -44.986% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.516% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 90.878% |
| GlycoMimetics, Inc. | 45.31 Million USD | 38.024% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 98.112% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -549.613% |
| SciSparc Ltd. | 11.18 Million USD | -151.164% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -549.613% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -54.17% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -129.969% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 50.642% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -142.406% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 91.773% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 79.687% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.267% |
| ADMA Biologics, Inc. | 329.18 Million USD | 91.468% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 76.042% |
| Clene Inc. | 52.34 Million USD | 46.342% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 93.968% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 91.04% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 78.378% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 95.704% |
| Adicet Bio, Inc. | 207.29 Million USD | 86.452% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 78.46% |
| Absci Corporation | 234.48 Million USD | 88.022% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -530.534% |
| Quantum-Si incorporated | 298.25 Million USD | 90.583% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -264.311% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 92.005% |
| Surrozen, Inc. | 46.08 Million USD | 39.051% |
| Generation Bio Co. | 374.75 Million USD | 92.506% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 88.972% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 93.631% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 82.288% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 92.617% |
| Invivyd, Inc. | 229.18 Million USD | 87.745% |
| Cingulate Inc. | 3.49 Million USD | -704.402% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 96.672% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -130.787% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -140.36% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 84.602% |
| Jaguar Health, Inc. | 50.76 Million USD | 44.674% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -37.511% |
| 2seventy bio, Inc. | 565.42 Million USD | 95.033% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 17.44% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 89.541% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 96.25% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 52.183% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 72.894% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 71.21% |
| Kronos Bio, Inc. | 213.27 Million USD | 86.832% |
| Innoviva, Inc. | 1.24 Billion USD | 97.741% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 82.423% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 94.014% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 88.421% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 98.567% |
| Evaxion Biotech A/S | 12.88 Million USD | -117.907% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 88.858% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 96.269% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 87.565% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -68.893% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 57.246% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 77.691% |
| Clearmind Medicine Inc. | 4.32 Million USD | -549.46% |
| AlloVir, Inc. | 190.79 Million USD | 85.28% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 88.973% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 94.049% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -228.074% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 92.378% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 92.41% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -338.625% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 95.58% |
| ImmunityBio, Inc. | 504.45 Million USD | 94.433% |
| Korro Bio, Inc. | 221.66 Million USD | 87.33% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 92.539% |
| Kineta, Inc. | 10.28 Million USD | -173.176% |
| Lantern Pharma Inc. | 43.64 Million USD | 35.655% |
| BioVie Inc. | 25.2 Million USD | -11.412% |
| Codexis, Inc. | 136.56 Million USD | 79.434% |
| Celularity Inc. | 143.88 Million USD | 80.481% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 77.691% |
| Virax Biolabs Group Limited | 5.48 Million USD | -412.132% |
| Kodiak Sciences Inc. | 479.37 Million USD | 94.141% |
| Cibus, Inc. | 544.41 Million USD | 94.841% |
| Annexon, Inc. | 297.67 Million USD | 90.565% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 79.57% |
| Moderna, Inc. | 18.42 Billion USD | 99.848% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.061% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 83.767% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -33.784% |
| Immix Biopharma, Inc. | 19.92 Million USD | -40.953% |
| Eyenovia, Inc. | 28.77 Million USD | 2.412% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 87.817% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 90.754% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 89.785% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -288.776% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 53.903% |
| Alkermes plc | 2.13 Billion USD | 98.685% |
| Arcellx, Inc. | 825.13 Million USD | 96.596% |
| Moolec Science SA | 24.05 Million USD | -16.772% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 65.597% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 72.387% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 93.925% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 8.666% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 95.28% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 82.097% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -301.514% |
| Humacyte, Inc. | 128.22 Million USD | 78.097% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 90.944% |
| Geron Corporation | 394.07 Million USD | 92.873% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 65.581% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -1418.118% |
| Royalty Pharma plc | 16.38 Billion USD | 99.829% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -133.512% |
| Notable Labs, Ltd. | 19.54 Million USD | -43.724% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 87.576% |
| Structure Therapeutics Inc. | 482.01 Million USD | 94.173% |
| IN8bio, Inc. | 33.7 Million USD | 16.683% |
| 89bio, Inc. | 596.26 Million USD | 95.29% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 48.144% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 84.001% |
| Acasti Pharma Inc. | 73.3 Million USD | 61.685% |
| Genelux Corporation | 27.89 Million USD | -0.689% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 68.586% |
| Liquidia Corporation | 120.43 Million USD | 76.679% |
| Mustang Bio, Inc. | 17.74 Million USD | -58.298% |
| Immunovant, Inc. | 666.71 Million USD | 95.788% |
| Vericel Corporation | 353.65 Million USD | 92.059% |
| Quantum-Si incorporated | 298.25 Million USD | 90.583% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 80.551% |
| XOMA Corporation | 234.3 Million USD | 88.013% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 87.956% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -516.947% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -7.537% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 73.847% |
| Vaxcyte, Inc. | 1.4 Billion USD | 98.005% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 97.089% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -530.534% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -23.283% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 45.575% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 37.984% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 91.56% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 84.457% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 23.746% |
| PepGen Inc. | 143.05 Million USD | 80.367% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 26.511% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.608% |
| Solid Biosciences Inc. | 164.93 Million USD | 82.972% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -378.269% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -288.776% |
| Immuneering Corporation | 102.58 Million USD | 72.622% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -551.837% |
| Silo Pharma, Inc. | 7.74 Million USD | -262.57% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -488.323% |
| Belite Bio, Inc | 94.64 Million USD | 70.325% |
| Pharming Group N.V. | 462.85 Million USD | 93.932% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -48.413% |
| Bionomics Limited | 27.64 Million USD | -1.577% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 83.834% |
| uniQure N.V. | 831.68 Million USD | 96.623% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 13.333% |
| GeoVax Labs, Inc. | 9.28 Million USD | -202.537% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 89.746% |
| Altimmune, Inc. | 210.64 Million USD | 86.667% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -589.526% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 73.847% |
| Peak Bio, Inc. | 2.59 Million USD | -981.691% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -699.464% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -137.587% |
| Benitec Biopharma Inc. | 52.21 Million USD | 46.207% |
| Zura Bio Limited | 100.84 Million USD | 72.15% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 96.39% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -326.404% |
| Compugen Ltd. | 121.33 Million USD | 76.853% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -441.149% |
| argenx SE | 4.54 Billion USD | 99.382% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 83.702% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -46.391% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 91.785% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 19.233% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 95.615% |
| PolyPid Ltd. | 15.37 Million USD | -82.703% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 76.456% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -146.621% |
| Forte Biosciences, Inc. | 38.98 Million USD | 27.95% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 84.345% |
| Instil Bio, Inc. | 325.63 Million USD | 91.375% |
| Elevation Oncology, Inc. | 89.09 Million USD | 68.476% |
| Immunome, Inc. | 148.54 Million USD | 81.093% |
| Verona Pharma plc | 308.12 Million USD | 90.885% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -359.097% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 67.703% |
| Shattuck Labs, Inc. | 159.56 Million USD | 82.399% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 85.097% |
| Design Therapeutics, Inc. | 289.64 Million USD | 90.304% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 61.435% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -418.368% |
| Achilles Therapeutics plc | 161.45 Million USD | 82.605% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 63.149% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 51.507% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 94.666% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 98.076% |
| Moolec Science SA | 24.05 Million USD | -16.772% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 44.602% |
| AEON Biopharma, Inc. | 6.84 Million USD | -310.302% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 78.791% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 89.67% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 96.401% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 89.481% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 83.761% |
| Athira Pharma, Inc. | 160.24 Million USD | 82.474% |
| HCW Biologics Inc. | 28.51 Million USD | 1.503% |
| XOMA Corporation | 234.3 Million USD | 88.013% |
| NeurAxis, Inc. | 509.49 Thousand USD | -5412.323% |
| Lumos Pharma, Inc. | 40.63 Million USD | 30.889% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 67.703% |
| 180 Life Sciences Corp. | 5.25 Million USD | -433.992% |
| Nektar Therapeutics | 398.03 Million USD | 92.944% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 19.233% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 60.122% |
| Arvinas, Inc. | 1.3 Billion USD | 97.847% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -228.074% |
| Palisade Bio, Inc. | 14.05 Million USD | -99.866% |
| Nutriband Inc. | 7.51 Million USD | -273.614% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -64.845% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 85.908% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 86.645% |
| Merus N.V. | 458.49 Million USD | 93.874% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 86.257% |
| Neurogene Inc. | 222.57 Million USD | 87.382% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 95.657% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -352.841% |
| CervoMed Inc. | 9.97 Million USD | -181.626% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 93.801% |
| Sesen Bio, Inc. | 189.17 Million USD | 85.154% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 84.415% |
| Rezolute, Inc. | 132.73 Million USD | 78.841% |
| Clene Inc. | 52.34 Million USD | 46.342% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -88.19% |
| BeyondSpring Inc. | 24.8 Million USD | -13.21% |
| Synlogic, Inc. | 75.55 Million USD | 62.826% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -136.766% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -199.927% |
| Peak Bio, Inc. | 2.59 Million USD | -981.691% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 83.936% |
| Krystal Biotech, Inc. | 818.35 Million USD | 96.568% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 88.319% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 96.13% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -685.122% |
| MannKind Corporation | 475.19 Million USD | 94.09% |
| Ikena Oncology, Inc. | 192.09 Million USD | 85.379% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -109.998% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 75.901% |
| Gossamer Bio, Inc. | 311.91 Million USD | 90.996% |
| CohBar, Inc. | 16.36 Million USD | -71.61% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 20.129% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -283.94% |
| Legend Biotech Corporation | 1.84 Billion USD | 98.481% |
| Mural Oncology plc | 301.74 Million USD | 90.692% |
| Disc Medicine, Inc. | 367.99 Million USD | 92.368% |
| Champions Oncology, Inc. | 26.13 Million USD | -7.474% |
| REGENXBIO Inc. | 573.97 Million USD | 95.107% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -937.086% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 81.808% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -132.578% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 91.741% |
| Vaxart, Inc. | 91.83 Million USD | 69.416% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 53.116% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 81.065% |
| Cellectis S.A. | 334.27 Million USD | 91.598% |
| Longeveron Inc. | 12.17 Million USD | -130.622% |
| Repare Therapeutics Inc. | 253.9 Million USD | 88.939% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.14% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 86.017% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 98.655% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -1628.319% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 89.887% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 82.78% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 79.758% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -10.043% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.876% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 97.566% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -129.969% |
| Veru Inc. | 50.59 Million USD | 44.491% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 38.346% |
| Cingulate Inc. | 3.49 Million USD | -704.402% |
| Passage Bio, Inc. | 150.54 Million USD | 81.344% |
| Context Therapeutics Inc. | 16.06 Million USD | -74.847% |
| Exicure, Inc. | 11.58 Million USD | -142.532% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 92.531% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 82.625% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -60.744% |
| Nuvalent, Inc. | 732.38 Million USD | 96.165% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -87.935% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 68.639% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -97.908% |
| OmniAb, Inc. | 401.98 Million USD | 93.013% |
| Anew Medical, Inc. | 19.45 Million USD | -44.353% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -5.083% |
| Lipocine Inc. | 23 Million USD | -22.104% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 79.911% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 90.809% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 66.542% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 76.892% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -253.94% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 96.817% |
| Ocugen, Inc. | 64.54 Million USD | 56.489% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 77.449% |
| Q32 Bio Inc. | 306.11 Million USD | 90.825% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -567.423% |
| Alumis Inc. Common Stock | 89.61 Million USD | 68.659% |
| Equillium, Inc. | 50.53 Million USD | 44.419% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 62.65% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 31.954% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -1551.241% |
| Dominari Holdings Inc. | 57.55 Million USD | 51.205% |
| Edesa Biotech, Inc. | 8.89 Million USD | -215.903% |
| vTv Therapeutics Inc. | 11.01 Million USD | -154.903% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.002% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 97.003% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 96.539% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 89.885% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 32.653% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 95.793% |
| Nkarta, Inc. | 378.88 Million USD | 92.587% |
| BioCardia, Inc. | 2.98 Million USD | -840.247% |
| Iterum Therapeutics plc | 26.25 Million USD | -6.954% |